Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Clinical Cancer Research|2016Cited by 51
Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre studyDavid L. Phelps, Sadaf Ghaem‐Maghami, Jane Borley et al.|British Journal of Cancer|2017Cited by 33
Supplementary Figure S1 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Unknown|2023Cited by 0
Supplementary Figure S4 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Pei Y. Teo et al.|Unknown|2023Cited by 0
Supplementary Figure S3 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Unknown|2023Cited by 0